SUPPORT PROGRAMME FOR PATIENTS RECEIVING IMRALDI OR BENEPALI THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERS: 12-MONTH PERSISTENCE

被引：0
|
作者：
Clark, Andrew [1 ]
Shering, Teresa [1 ]
Addison, Janet [2 ]
机构：
[1] Biogen Idec Ltd, Maidenhead, Berks, England
[2] Biogen Idec Ltd, Clin Res, Maidenhead, Berks, England
来源：
RHEUMATOLOGY | 2024年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P067
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Support Programme for Patients Receiving Imraldi or Benepali Therapy for Immune-Mediated Inflammatory Disorders: 12-Month Persistence
    Clark, Andrew
    Shering, Teresa
    Addison, Janet
    RHEUMATOLOGY, 2024, 63
  • [2] Methylprednisolone-Induced Lymphocytosis in Patients with Immune-Mediated Inflammatory Disorders
    Bromberg, Laura
    Roufosse, Florence
    Pradier, Olivier
    Delporte, Cedric
    Van Antwerpen, Pierre
    De Maertelaer, Viviane
    Cogan, Elie
    AMERICAN JOURNAL OF MEDICINE, 2016, 129 (07): : 746 - +
  • [3] Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus
    D'Amico, Ferdinando
    Solitano, Virginia
    Aletaha, Daniel
    Hart, Ailsa
    Magro, Fernando
    Selmi, Carlo
    Ng, Siew C.
    Al Awadhi, Sameer
    Choy, Ernest
    Schulze-Koops, Hendrik
    Bossuyt, Peter
    Olivera, Pablo A.
    Kotze, Paulo Gustavo
    Ghosh, Subrata
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    AUTOIMMUNITY REVIEWS, 2021, 20 (07)
  • [4] Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review
    Depont, Fanny
    Berenbaum, Francis
    Filippi, Jerome
    Le Maitre, Michel
    Nataf, Henri
    Paul, Carle
    Peyrin-Biroulet, Laurent
    Thibout, Emmanuel
    PLOS ONE, 2015, 10 (12):
  • [5] 12-MONTH PERSISTENCE WITH DENOSUMAB THERAPY AMONG OSTEOPOROTIC WOMEN IN THE CANADIAN PATIENT-SUPPORT PROGRAM
    Papaioannou, A.
    Khan, A.
    Belanger, A.
    Bensen, W.
    Kendler, D. L.
    Theoret, F.
    Amin, M.
    Brekke, L.
    Erdmann, M.
    Popovic, V.
    Walker, V.
    Adachi, J. D.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S221 - S221
  • [6] Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases
    Wieske, Luuk
    Stalman, Eileen W.
    van Dam, P. J. Koos
    Kummer, Laura Y.
    Steenhuis, Maurice
    van Kempen, Zoe L. E.
    Killestein, Joep
    Volkers, Adriaan G.
    Tas, Sander W.
    Boekel, Laura
    Wolbink, Gertjan
    van der Kooi, Anneke
    Raaphorst, Joost
    Lowenberg, Mark
    Takkenberg, Bart
    D'Haens, Geert R. A. M.
    Spuls, Phyllis, I
    Bekkenk, Marcel W.
    Musters, Annelie H.
    Post, Nicoline F.
    Bosma, Angela L.
    Hilhorst, Marc L.
    Vegting, Yosta
    Bemelman, Frederique J.
    Voskuyl, Alexandre
    Broens, Bo
    Parra Sanchez, Agner
    van Els, Cecile A. C. M.
    De Wit, Jelle
    Rutgers, Abraham
    de Leeuw, Karina
    Horvath, Barbara
    Verschuuren, Jan J. G. M.
    Ruiter, Annabel M.
    van Ouwerkerk, Lotte
    van der Woude, Diane
    Allaart, Cornelia F.
    Teng, Y. K. Onno
    van Paassen, Pieter
    Busch, Matthias H.
    Jallah, Papay B. P.
    Brusse, Esther
    van Doorn, Pieter A.
    Baars, Adaja Elisabeth
    Hijnen, Dirkjan
    Schreurs, Corine R. G.
    Van der Pol, W. Ludo
    Goedee, H. Stephan
    Keijzer, Sofie
    Keijser, Jim
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (06) : 883 - 885
  • [7] THE RISK OF TUBERCULOSIS IN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISORDERS RECEIVING BIOLOGICAL THERAPY: A 15-YEAR EXPERIENCE IN A ROMANIAN COHORT
    Codrina, Ancuta
    Pomirleanu, Cristina
    Strugariu, Georgiana
    Petrariu, Luiza
    Paiu, Raluca
    Ancuta, Eugen
    Bran, Codruta
    Chirieac, Rodica
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 699 - 700
  • [8] Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?
    Elverdi, Tugrul
    Ozer Cerme, Melis Dila
    Aydin, Tahacan
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (10) : 1183 - 1188
  • [9] Immunomodulator and biological therapy are increased in inflammatory bowel disease patients with associated immune-mediated inflammatory diseases
    Garcia Garcia, M. J.
    Pascual Mato, M.
    Del Pozo Calzada, C.
    Rasines Perez, L.
    Castro Senosiain, B.
    Crespo Garcia, J.
    Rivero Tirado, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S245 - S246
  • [10] Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents
    Fiorino, Gionata
    Danese, Silvio
    Pariente, Benjamin
    Allez, Matthieu
    AUTOIMMUNITY REVIEWS, 2014, 13 (01) : 15 - 19
12345